BRCA1/2 Flu Vaccine

Running, not enrolling

Conditions studied: BRCA1 Mutation, BRCA2 Mutation

In brief

To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impacts overall immune health and fitness.

Key facts

Study ID

NCT04499534

Run by

Abramson Cancer Center at Penn Medicine

People needed

50

Starts

2019-10-28

Expected to finish

2027-06-01

Last updated by the study team

2026-07-08

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males and females
• Over age 25
• BRCA1 or BRCA2 pathogenic or likely pathogenic mutation
• No personal cancer history apart from non melanoma skin cancer, localized thyroid cancer, in situ cancers of any type
• Participants must sign the informed consent form

You may not qualify if…

• Are allergic to influenza vaccination
• Have received influenza vaccination within the past 6 months
• Require prednisone, methotrexate, or other immunosuppressing medications
• Have HIV infection
• Have a history of solid organ tumor or bone marrow transplant
• Require combination immunotherapy;
• Are on other studies requiring blood draws that might exceed 450 mL total during the period of the influenza vaccine study

Where it is running

• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.